Contents
Key Takeaways
- PayPal (PYPL) shares declined following 2026 guidance projecting flat or modestly lower adjusted earnings, yet turnaround prospects persist
- CVS Health (CVS) delivered $402.1 billion in 2025 full-year sales and expects at least $400 billion for 2026
- Nike (NKE) generated $11.3 billion in fiscal Q3 2026 sales, with wholesale channels advancing 5% and North American operations returning to growth
- HP (HPQ) delivered Q1 2026 sales of $14.4 billion, representing 6.9% annual growth, while maintaining free cash flow targets of $2.8–$3.0 billion
- Estée Lauder (EL) stock tumbled when fiscal 2026 projections fell short of market expectations despite surpassing profit forecasts
Investors hunting for value opportunities in 2026 are zeroing in on PayPal (PYPL), CVS Health (CVS), Nike (NKE), HP (HPQ), and Estée Lauder (EL).
These aren’t merely discounted equities. They represent a specific investment profile: subdued market confidence paired with tangible business drivers that could reshape their Wall Street valuations.
Potential Turnaround Candidates
PayPal (PYPL)
PayPal stands out as a prime illustration of diminished expectations confronting a potential recovery trajectory. According to Reuters reporting from February, the payments giant projected 2026 adjusted earnings would remain flat or decline modestly, falling short of analyst projections.
The equity experienced significant selling pressure following leadership transitions that sparked concerns about strategic execution. However, should the team successfully accelerate branded checkout adoption and unlock greater Venmo revenue streams, market participants may begin valuing it as a fintech platform in recovery mode.
CVS Health (CVS)
CVS Health continues trading at compelling multiples when measured against its business scale. The healthcare giant posted 2025 full-year revenue reaching $402.1 billion. Company leadership established 2026 adjusted earnings per share targets between $7.00 and $7.20, supported by revenue projections of at least $400 billion.
The shares don’t require a complete turnaround to appreciate meaningfully. Sufficient margin expansion across its insurance and pharmacy segments could prompt the market to recognize it as a stable cash-generating enterprise.
Nike (NKE)
Nike remains perceived by market participants as a complex turnaround situation with numerous variables. The athletic apparel leader’s fiscal Q3 2026 results, disclosed March 31, showed revenue hitting $11.3 billion while wholesale channels climbed 5%. North American markets also expanded.
Gross profitability contracted, and certain business segments continue facing headwinds. Nevertheless, select operational metrics are trending favorably—precisely where value opportunities frequently emerge.
Cash Generation and Recovery Scenarios
HP (HPQ)
HP delivered fiscal Q1 2026 revenue totaling $14.4 billion, marking 6.9% year-over-year expansion. Non-GAAP diluted earnings per share increased 9.5%, while free cash flow reached $175 million. The technology company reaffirmed its annual free cash flow guidance spanning $2.8 billion to $3.0 billion.
The bullish argument hinges on sustained PC market stabilization combined with accelerating AI PC adoption. HP doesn’t require explosive top-line expansion to drive share appreciation—merely consistent profitability and cash flow performance.
Estée Lauder (EL)
Estée Lauder represents the most speculative opportunity among these five names. Reuters coverage from February highlighted that shares declined following disappointing fiscal 2026 guidance, notwithstanding better-than-expected quarterly profits.
Executives outlined plans to drive transformation through fresh product introductions, enhanced marketing initiatives, and premium brand positioning. Market sentiment remains skeptical given persistent U.S. demand weakness, tariff uncertainties, and execution challenges.
Based on its latest projections, Estée Lauder has yet to demonstrate reliable revenue expansion or margin restoration.
Final Thoughts
These five equities share a unifying characteristic. Market sentiment remains reserved, yet each possesses a legitimate catalyst capable of transforming its 2026 valuation.
